Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
- 1 September 1992
- journal article
- Published by Elsevier in Human Pathology
- Vol. 23 (9) , 974-979
- https://doi.org/10.1016/0046-8177(92)90257-4
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Dysplasia and the natural history of cervical cancer: Early results of the Toronto cohort studyEuropean Journal of Cancer and Clinical Oncology, 1991
- Direct Interaction of a Ligand for the erb B2 Oncogene Product with the EGF Receptor and p185
erb
B2
Science, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast CancerNew England Journal of Medicine, 1989
- Immunohistochemical distribution of c‐erbB‐2 in infiltrating and in situ breast cancerInternational Journal of Cancer, 1988
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogeneCell, 1988
- Cellular and molecular aspects of neoplastic progression in the mammary glandEuropean Journal of Cancer and Clinical Oncology, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985